Literature DB >> 11816870

Suicide in primary affective disorders revisited: a systematic review by treatment era.

D O'Leary1, E Paykel, C Todd, K Vardulaki.   

Abstract

BACKGROUND: We reviewed suicide rates in affective disorder and their variation with electroconvulsive therapy (ECT) and antidepressant availability.
METHOD: Suicide rates were calculated from 75 follow-up studies, identified by systematic literature searches and analyzed for differences over time eras characterized by the availability of specific treatments. DATA SOURCES AND STUDY SELECTION: MEDLINE, EMBASE, BIOSIS Previews, and Psychological Abstracts literature searches were conducted for the years 1966 to 1995. References from review articles identified from these sources from 1985 onward and textbook references were also included. Publications prior to 1966 were obtained from article references identified for the period 1966 to 1976 and reviews. Inclusion criteria were (1) articles written in English, French, or German; (2) sample size > 30; (3) age at recruitment between 18 and 64 years for each subject; (4) sample had to contain subjects hospitalized at time of recruitment; and (5) naturalistic follow-up of at least 6 months.
RESULTS: Suicide rates decreased with longer follow-up periods. For follow-up periods over 20 years, the mean rate was 3.76/1,000 person-years (95% confidence interval [CI] = 2.35 to 5.17). Suicides accounted for 12.3% (95% CI = 8.52 to 16.04) of all deaths in samples in which 40% or more of patients had died. For studies with minimal overlap between eras, the mean suicide rate differed significantly between eras (pretreatment, before 1940: 6.3/1000; ECT treatment, 1940 to 1959: 5.7/1,000: antidepressant treatment, 1960 onward: 3.3/1,000; F = 31.4. df = 2,42; p < .001).
CONCLUSION: The risk of suicide in follow-up studies of affective disorder has decreased compared to that reported in previous reviews. The availability of ECT and antidepressants may have contributed to this decrease, but prescription of these treatments cannot be assumed for all patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11816870     DOI: 10.4088/jcp.v62n1009

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  [Depressive disorders. A diagnostic and therapeutic challenge also for primary care].

Authors:  H-P Kapfhammer
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

Review 2.  Suicidal behaviour in bipolar disorder: risk and prevention.

Authors:  Leonardo Tondo; Göran Isacsson; Ross Baldessarini
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  The bipolar patient with comorbid substance use disorder: recognition and management.

Authors:  Mark J Albanese; Ronald Pies
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  The impact of residual symptoms on outcome of major depression.

Authors:  Noel Kennedy; Kevin Foy
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

Review 5.  Somatic symptoms in depression.

Authors:  Hans-Peter Kapfhammer
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 6.  Antidepressants and Suicide Risk: A Comprehensive Overview.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Elisa Ambrosi; Gloria Giordano; Paolo Girardi; Roberto Tatarelli; David Lester
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-30

7.  The Symptom Structure of Postdisaster Major Depression: Convergence of Evidence from 11 Disaster Studies Using Consistent Methods.

Authors:  Carol S North; David Baron
Journal:  Behav Sci (Basel)       Date:  2021-01-13

Review 8.  Effects of somatic treatments on suicidal ideation and completed suicides.

Authors:  Elise M Hawkins; William Coryell; Stephen Leung; Sagar V Parikh; Cody Weston; Paul Nestadt; John I Nurnberger; Adam Kaplin; Anupama Kumar; Ali A Farooqui; Rif S El-Mallakh
Journal:  Brain Behav       Date:  2021-10-17       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.